This interview was a "tour de force" Lots of fo
Post# of 155062
(Total Views: 624)
Posted On: 04/02/2020 3:10:58 PM
This interview was a "tour de force"
Lots of food to chew but 3 things are outstanding:
1) Dr. Patterson mentioned reductions of IL-6 to 90% Holy Cow !!. This is extraordinary !!! (first patient had 70%).
2) With the data we have now there is "mission accomplished". Of 10 severely immuno-depressed patients already there are 7 out of the woods (1 discharged and two more out of ICU, did everybody hear that ???). This is 70% vs 96% for China (or whatever number we want to use). Please remember, these folks where in very bad shape and maybe more to come out of ICUs (or hospital). As per Patterson words:
3) Trials in Harvard, Cornell, UCLA, San Francisco and Massachusetts general. Injecting today or tomorrow.
So, some lives have been saved, the numbers look very good and there are more good news coming … These numbers will get us approved for sure. The good thing (repeating once more) is that Patterson has DATA to present to FDA. Once the trials start they know what to look for.
Lots of food to chew but 3 things are outstanding:
1) Dr. Patterson mentioned reductions of IL-6 to 90% Holy Cow !!. This is extraordinary !!! (first patient had 70%).
2) With the data we have now there is "mission accomplished". Of 10 severely immuno-depressed patients already there are 7 out of the woods (1 discharged and two more out of ICU, did everybody hear that ???). This is 70% vs 96% for China (or whatever number we want to use). Please remember, these folks where in very bad shape and maybe more to come out of ICUs (or hospital). As per Patterson words:
Quote:
They had one direction to go when we intervened
3) Trials in Harvard, Cornell, UCLA, San Francisco and Massachusetts general. Injecting today or tomorrow.
So, some lives have been saved, the numbers look very good and there are more good news coming … These numbers will get us approved for sure. The good thing (repeating once more) is that Patterson has DATA to present to FDA. Once the trials start they know what to look for.
(9)
(0)